Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Status Completed

Clinical Trial Summary

The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.

Clinical Trial Description

- Participants will receive Darbepoetin alfa through an injection under the skin, about 28-35 days after their allogeneic stem cell transplant. They will continue to receive the study drug once every three weeks for a maximum of four doses.

- Blood tests will be performed at weeks 3, 6, 9 and 12. The blood tests done at week three will check to make sure the participant has enough iron in their system. If not, they will need to take an iron supplement. Participants will also take a folate supplement to help cell growth and reproduction. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Hematologic Malignancies

Clinical Trial Details

NCT number	NCT00355407
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	N/A
Start date	June 2006
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05433090` - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies	N/A
Completed	`NCT00061620` - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies	Phase 1
Enrolling by invitation	`NCT02473757` - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Not yet recruiting	`NCT06296368` - DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics	N/A
Recruiting	`NCT02032446` - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease	Phase 1/Phase 2
Recruiting	`NCT02884375` - Elderly CAncer Patient	N/A
Recruiting	`NCT01203722` - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT00780052` - Infusional C-myb ASODN in Advanced Hematologic Malignancies	Phase 1
Recruiting	`NCT04098393` - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation	Phase 1
Recruiting	`NCT06028828` - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT04538599` - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies	Phase 1
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05849207` - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant	Phase 1
Not yet recruiting	`NCT05028478` - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02494258` - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders	Phase 2
Completed	`NCT03212560` - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting	`NCT02600208` - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT01949545` - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment	Phase 1